The Gestational Diabetes Market is witnessing steady growth driven by rising maternal health awareness, increasing obesity rates, and the global emphasis on early diagnosis and management of diabetes during pregnancy. Gestational diabetes mellitus (GDM) affects about 14% of pregnancies worldwide, translating to nearly 18 million cases annually. The prevalence is increasing due to lifestyle changes, advanced maternal age, and the growing burden of type 2 diabetes risk factors among women of childbearing age.
According to the International Diabetes Federation (IDF), over 21 million live births were affected by some form of hyperglycemia in pregnancy in 2024, of which 84% were due to gestational diabetes. The economic burden of untreated or poorly managed GDM can lead to higher maternal and neonatal complications, including preeclampsia, macrosomia, and long-term metabolic disorders in both mother and child.
The global gestational diabetes market size is calculated at USD 10.3 billion in 2025, grew to USD 11.24 billion in 2026, and is projected to reach around USD 24.62 billion by 2035. The market is expanding at a CAGR of 9.15% between 2026 and 2035.
Gestational diabetes mellitus (GDM) is a type of diabetes that develops during pregnancy when the body cannot produce enough insulin to regulate blood sugar levels effectively. Unlike Type 1 or Type 2 diabetes, GDM typically appears in the second or third trimester and often resolves after childbirth. However, it poses serious risks to both the mother and the baby if left unmanaged.
Maternal health solutions are becoming central to healthcare strategies worldwide due to their direct impact on reducing maternal and infant morbidity. Gestational diabetes represents a key intersection of maternal and metabolic health. The World Health Organization (WHO) emphasizes that screening and managing gestational diabetes can reduce complications by up to 40% in both mother and newborn.
Developed countries like the U.S., Germany, and Japan are integrating gestational diabetes screening as part of standard prenatal care. Meanwhile, emerging economies such as India and Brazil are expanding awareness and implementing national diabetes programs to tackle maternal health challenges.
Moreover, healthcare systems are shifting from episodic to continuous glucose monitoring (CGM) approaches. This transition allows real-time tracking of maternal glucose levels, personalized treatment, and data-driven interventions reducing hospital visits and improving pregnancy outcomes.
Recent technological breakthroughs have transformed gestational diabetes care. Traditional glucose meters are being replaced by connected and wearable devices that offer real-time analytics and cloud-based data sharing between patients and healthcare providers.
Key advancements include:
By 2025, the global adoption of connected diabetes care solutions for pregnancy is expected to grow by over 30% year-on-year, reflecting a major shift toward precision maternal care.
| Company | Headquarters | Annual Revenue (2024, USD Billion) | Established Year |
| F. Hoffmann-La Roche Ltd. | Basel, Switzerland | 69.0 | 1896 |
| Biocon Limited | Bengaluru, India | 1.3 | 1978 |
| Johnson & Johnson | New Brunswick, New Jersey, U.S. | 88.6 | 1886 |
| Merck & Co., Inc. | Rahway, New Jersey, U.S. | 63.1 | 1891 |
| AstraZeneca plc | Cambridge, United Kingdom | 45.8 | 1999 |
Headquartered in Basel, Switzerland, founded in 1896, Roche is a global leader in diagnostics and pharmaceuticals.
The company offers glucose monitoring systems, insulin delivery tools, and digital diabetes management platforms.
Roche’s diabetes care segment contributes significantly to its diagnostics business, valued at around USD 14.9 billion in 2024.
Partnered with Novo Nordisk to develop integrated diabetes care models for women with GDM.
Expanded its Accu-Chek product line with next-gen connected glucose meters featuring AI-based alerts for pregnant women.
Collaborated with healthcare providers in Asia-Pacific to improve access to point-of-care GDM diagnostics.
Strong market presence in Europe, North America, and Asia-Pacific.
Increased adoption of Roche’s digital diabetes ecosystem in India and China, improving early diagnosis rates.
Contributed to national health programs supporting maternal glucose monitoring.
In 2025, Roche launched Accu-Chek Instant WomenCare, a device designed for pregnancy-safe glucose testing.
The company is investing in AI-driven data analytics for maternal diabetes management.
Announced sustainability initiatives in production facilities for healthcare diagnostics.
Headquartered in Bengaluru, India, established in 1978, Biocon is a global biopharmaceutical company specializing in biosimilars, generics, and insulin products.
The company produces Insulin Glargine and Insulin Aspart, widely used in GDM management.
Biocon’s insulin franchise generated USD 1.3 billion in revenue in 2024.
Partnered with Viatris Inc. for commercializing insulin biosimilars across over 60 countries.
Expanded insulin manufacturing capacity in Malaysia to meet growing global demand.
Collaborated with India’s Ministry of Health to support national gestational diabetes screening programs.
A key insulin supplier to Asia, Africa, and Latin America.
Biocon’s affordable insulin has significantly reduced the cost of GDM management in developing nations.
Plays a crucial role in advancing equitable access to maternal diabetes therapy.
In 2025, Biocon launched Insugen SmartPen, a user-friendly insulin delivery device designed for pregnant women.
The company announced expansion into Europe’s biosimilar insulin market.
Introduced digital glucose tracking collaborations for maternal health programs.
Founded in 1886 and headquartered in New Brunswick, New Jersey, USA, Johnson & Johnson (J&J) is one of the largest healthcare conglomerates in the world.
Operates through its MedTech and Innovative Medicine divisions, providing glucose monitoring, medical devices, and maternal care solutions.
Reported USD 88.6 billion in total revenue in 2024.
Partnered with Google’s Verily Life Sciences to develop next-generation smart diabetes management platforms.
Expanded J&J’s LifeScan glucose monitoring brand in developing markets.
Investing in R&D for AI-enabled pregnancy health tracking technologies.
Strong footprint in North America, Europe, and Asia-Pacific.
Implements community maternal health initiatives in Africa and Latin America.
Actively contributes to global maternal well-being programs supported by WHO.
In 2025, J&J launched OneTouch Verio Advance, a smart glucose system with pregnancy mode features.
The company announced collaborations to integrate glucose data into electronic maternal health records.
Received recognition for sustainability and women’s healthcare initiatives globally.
Headquartered in Rahway, New Jersey, USA, founded in 1891, Merck is a leading biopharmaceutical company with strong expertise in endocrinology and women’s health.
Offers insulin analogs and oral antidiabetic drugs used in GDM management.
Generated USD 63.1 billion in revenue in 2024.
Partnered with Bill & Melinda Gates Foundation to improve maternal diabetes management in low-income regions.
Expanded its women’s health R&D portfolio to include pregnancy-safe glucose control medications.
Strengthened collaborations with digital health firms to enhance maternal care monitoring.
Merck’s diabetes medications are approved in over 120 countries.
Major presence in North America, Europe, and Asia-Pacific.
Supports programs improving maternal health in developing countries.
In 2025, Merck announced new clinical data for its oral insulin candidates.
The company launched a maternal health education initiative in India and Sub-Saharan Africa.
Investing in AI-driven predictive analytics for gestational health risks.
Headquartered in Cambridge, United Kingdom, established in 1999 through the merger of Astra AB and Zeneca Group.
AstraZeneca focuses on metabolic diseases, with drugs like Farxiga (dapagliflozin) being evaluated for safe use in gestational diabetes.
Reported USD 45.8 billion in revenue in 2024.
Collaborated with Sanofi and Oxford University for diabetes and maternal metabolic research.
Expanded its metabolic R&D centers in Sweden and the U.S.
Partnered with NHS England for clinical evaluation of diabetes drugs during pregnancy.
Strong market presence across Europe, North America, and Asia-Pacific.
Supports maternal health initiatives in developing regions via AstraZeneca Foundation.
Plays a major role in metabolic health awareness and research collaborations.
In 2025, AstraZeneca began clinical trials on novel pregnancy-safe glucose modulators.
Expanded its digital patient engagement tools for pregnant women with GDM.
Announced sustainability goals focusing on green manufacturing for metabolic drugs.
Partner with our experts to explore the Gestational Diabetes Market at sales@towardshealthcare.com
